EUCTR2015-000640-42-DE进行中（未招募）1 期
A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) - Safety, tolerability and PK of nintedanib iin combination with pirfenidone in IPF
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent consistent with ICH-GCP and local laws, signed prior to any study procedures being performed (including any required washout)
- •-Male or female patients aged greater than or equal to 40 years at visit 1
- •-Idiopathic Pulmonary Fibrosis (IPF) diagnosis, based upon the ATS/ERS/JRS/ALAT 2011 guideline and confirmed by the investigator based on chest high resolution computed tomography (HRCT) scan performed within 12 months of visit 1
- •-FVC greater than or equal to 50% of predicted normal at visit 1
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •-ALT, AST > 1.5 fold upper limit of normal (ULN) at visit 1
- •-Total bilirubin > 1.5 fold ULN at visit 1
- •-Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC <0.7) at visit 1
- •-History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1
- •-Bleeding Risk: Known genetic predisposition to bleeding, Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin etc) or high dose antiplatelet therapy, History of haemorrhagic central nervous system event within 12 months prior to visit 1, History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1, International normalised ratio (INR) > 2 at visit 1, Prothrombin time and partial thromboplastin time (PTT) > 150% of
- •institutional ULN at visit 1
- •-Planned major surgery during the trial participation, including lung transplantation,major abdominal or major intestinal surgery.
- •-History of thrombotic event (including stroke and transient ischemic attack) within 12
- •months of visit 1
- •-Severe renal impairment (Creatinine clearance <30 mL/min calculated by Cockcroft–Gault formula6 at visit 1) or end-stage renal disease requiring dialysis
- •-Treatment with NAC, prednisone >15 mg daily or >30 mg every 2 days OR equivalent
- •dose of other oral corticosteroids and/or fluvoxamine within 2 weeks of visit 2
- •-Treatment with azathioprine, cyclophosphamide, cyclosporine as well as any other
- •investigational drug within 8 weeks of visit 2
- •-Previous treatment with pirfenidone
- •-Permanent discontinuation of nintedanib in the past due to AEs considered drug-related
- •-Known hypersensitivity to nintedanib, pirfenidone, peanut or soya or to any of the
- •-A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial
- •-Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment
- •-Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
- •-Women of childbearing potential not willing or able to use highly effective methods of
- •birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year
- •when used consistently and correctly5 for 28 days prior to and 3 months after nintedanib administration
- •-Patients not able to understand and follow study procedures including completion of selfadministered questionnaires without help
- •-Patients who require dose reduction and/or temporary interruption during the run-in
- •period with nintedanib 150 mg bid
- •-Patients with underlying chronic liver disease (Child Pugh A, B or C hepatic impairment)
研究者
相似试验
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-ITBOEHRINGER-INGELHEIM ITALIA S.P.A.135
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFMedDRA version: 18.0Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-FRBoehringer Ingelheim France136
进行中（未招募）
1 期
Safety, tolerability and PK of nintedanib in combination with pirfenidone in IPFIdiopathic Pulmonary FibrosisEUCTR2015-000640-42-NLBoehringer Ingelheim bv135
已完成
4 期
A twelve week, open-label, randomised, parallel-group study evaluating safety, tolerability and pharmacokinetics (PK) of oral nintedanib in combination with oral pirfenidone, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis of unknown origin10024967NL-OMON43818Boehringer Ingelheim15
进行中（未招募）
不适用
A trial to evaluate the efficacy and safety of recombinant human growth hormone (hGH) (Norditropin® Nordilet®) therapy on height velocity (Ht-V) in patients with idiopathic short stature in KoreaMedDRA version: 19.0Level: LLTClassification code 10066333Term: Idiopathic short statureSystem Organ Class: 100000004859Idiopathic short statureEUCTR2015-002613-30-Outside-EU/EEAovo Nordisk A/S54